OliX Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
OliX Pharmaceuticals has a total shareholder equity of ₩26.4B and total debt of ₩44.0B, which brings its debt-to-equity ratio to 166.8%. Its total assets and total liabilities are ₩92.5B and ₩66.1B respectively.
Key information
166.8%
Debt to equity ratio
₩44.02b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩24.44b |
| Equity | ₩26.40b |
| Total liabilities | ₩66.10b |
| Total assets | ₩92.50b |
Recent financial health updates
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt
Nov 15
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely
Apr 13Recent updates
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt
Nov 15OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Oct 09Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower
Aug 22We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely
Apr 13Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year
Feb 17
Financial Position Analysis
Short Term Liabilities: A226950's short term assets (₩28.3B) do not cover its short term liabilities (₩31.3B).
Long Term Liabilities: A226950's short term assets (₩28.3B) do not cover its long term liabilities (₩34.8B).
Debt to Equity History and Analysis
Debt Level: A226950's net debt to equity ratio (74.2%) is considered high.
Reducing Debt: A226950's debt to equity ratio has increased from 0% to 166.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A226950 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A226950 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27% each year